PP2, a reversible ATP-competitive inhibitor of the Src family kinases (SFKs), demonstrates dual-targeting activity against both SRC and HIF1A. In the context of stroke, PP2 has been shown to attenuate blood–brain barrier (BBB) disruption by suppressing Src kinase phosphorylation (38). The gene discussed is SRC; the disease is stroke disorder.